+

WO2003038063A3 - Human secreted proteins - Google Patents

Human secreted proteins Download PDF

Info

Publication number
WO2003038063A3
WO2003038063A3 PCT/US2002/008277 US0208277W WO03038063A3 WO 2003038063 A3 WO2003038063 A3 WO 2003038063A3 US 0208277 W US0208277 W US 0208277W WO 03038063 A3 WO03038063 A3 WO 03038063A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Application number
PCT/US2002/008277
Other languages
French (fr)
Other versions
WO2003038063A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to CA002441755A priority Critical patent/CA2441755A1/en
Priority to EP02799146A priority patent/EP1390390A4/en
Priority to AU2002363296A priority patent/AU2002363296A1/en
Publication of WO2003038063A2 publication Critical patent/WO2003038063A2/en
Publication of WO2003038063A3 publication Critical patent/WO2003038063A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating hematopoietic and hematologic diseases, disorders, and/or conditions related thereto. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
PCT/US2002/008277 2001-03-21 2002-03-19 Human secreted proteins WO2003038063A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002441755A CA2441755A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A EP1390390A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002363296A AU2002363296A1 (en) 2001-03-21 2002-03-19 Human secreted proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Publications (2)

Publication Number Publication Date
WO2003038063A2 WO2003038063A2 (en) 2003-05-08
WO2003038063A3 true WO2003038063A3 (en) 2003-12-11

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/008277 WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Family Applications After (6)

Application Number Title Priority Date Filing Date
PCT/US2002/009785 WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008279 WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1390390A4 (en)
AU (6) AU2002363296A1 (en)
CA (7) CA2441702A1 (en)
WO (7) WO2003038063A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
EP1000084A4 (en) 1997-07-08 2003-03-26 Human Genome Sciences Inc 123 human secreted proteins
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
CA2358684C (en) 1999-01-15 2013-07-16 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1364021A2 (en) 2000-10-31 2003-11-26 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030119112A1 (en) 2001-06-20 2003-06-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003033727A1 (en) 2001-10-12 2003-04-24 Yamanouchi Pharmaceutical Co., Ltd. Method of screening cell death inhibitor
SI1997512T1 (en) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2453895T3 (en) 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
WO2006101474A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
PL1673450T3 (en) * 2003-10-14 2010-10-29 Baxalta Inc Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
EP1714154A2 (en) * 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2563735C (en) 2004-04-22 2020-07-14 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
ES2385657T3 (en) * 2004-09-01 2012-07-27 Dynavax Technologies Corporation Methods and compositions for the inhibition of innate immune responses and autoimmunity
EP1799850A4 (en) * 2004-09-07 2009-02-11 Telethon Inst For Child Health METHOD OF DIAGNOSING AND / OR PREDICTING DEVELOPMENT OF ALLERGIC DISEASE
EP2093297A3 (en) * 2004-09-07 2009-11-18 Telethon Institute for Child Health Research Agents for treatment or prevention of an allergic disorder
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
JP2008531026A (en) 2005-02-28 2008-08-14 バクスター・インターナショナル・インコーポレイテッド Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K-dependent protein expression
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090054307A1 (en) * 2005-09-01 2009-02-26 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
PL2845866T3 (en) 2006-10-27 2017-10-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2361980B1 (en) 2007-10-26 2016-12-07 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 Adiponectin receptor fragments and methods of use
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
IN2012DN03824A (en) 2009-10-30 2015-08-28 Merck Sharp & Dohme
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
AU2011268211B2 (en) 2010-06-16 2015-07-16 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
KR20130110170A (en) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. Substituted nucleotide analogs
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
KR102531889B1 (en) 2016-06-20 2023-05-17 키맵 리미티드 Anti-PD-L1 and IL-2 cytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20230125856A (en) 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Gene editing of pcsk9
KR102667951B1 (en) 2017-04-03 2024-05-22 에프. 호프만-라 로슈 아게 Antibodies binding to STEAP-1
EP3641951B1 (en) 2017-06-22 2023-09-20 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
US10450119B2 (en) * 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
GB2632564A (en) 2020-04-09 2025-02-12 Verve Therapeutics Inc Base editing of angptl3 and methods of using same for treatment of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins
CA2333917A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
US6174994B1 (en) * 1997-05-30 2001-01-16 Smithkline Beecham Corporation 7TM receptor (H2CAA71)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1390390A4 *

Also Published As

Publication number Publication date
CA2441397A1 (en) 2002-10-03
WO2003038063A2 (en) 2003-05-08
AU2002320013A1 (en) 2002-11-18
WO2002102993A2 (en) 2002-12-27
EP1379264A1 (en) 2004-01-14
WO2002090526A2 (en) 2002-11-14
WO2002102994A2 (en) 2002-12-27
EP1379264A4 (en) 2009-07-08
CA2441840A1 (en) 2002-11-28
EP1379132A4 (en) 2009-07-01
EP1423134A2 (en) 2004-06-02
EP1414845A4 (en) 2009-07-08
CA2441755A1 (en) 2003-05-08
AU2002326293A1 (en) 2003-01-02
AU2002332391A1 (en) 2003-01-02
WO2002095010A2 (en) 2002-11-28
EP1404702A2 (en) 2004-04-07
WO2002095010A3 (en) 2004-02-12
CA2441832A1 (en) 2002-12-27
EP1404702A4 (en) 2009-07-08
WO2002102993A3 (en) 2004-03-25
EP1381622A2 (en) 2004-01-21
EP1390390A2 (en) 2004-02-25
EP1390390A4 (en) 2009-07-08
WO2002102994A3 (en) 2003-07-24
AU2002354719A1 (en) 2003-01-21
EP1414845A2 (en) 2004-05-06
CA2441417A1 (en) 2002-11-14
EP1379132A2 (en) 2004-01-14
AU2002363296A1 (en) 2003-05-12
AU2002324424A1 (en) 2002-12-03
WO2003004622A2 (en) 2003-01-16
WO2002090526A3 (en) 2003-10-30
CA2441416A1 (en) 2003-01-16
WO2002076488A1 (en) 2002-10-03
CA2441702A1 (en) 2002-12-27
WO2003004622A3 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
WO2003038063A3 (en) Human secreted proteins
WO2002092787A3 (en) Human secreted proteins
WO2001055364A8 (en) Nucleic acids, proteins, and antibodies
WO2001090304A3 (en) Nucleic acids, proteins, and antibodies
WO2001054472A8 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2004042000A3 (en) 157 human secreted proteins
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2001055440A8 (en) Nucleic acids, proteins, and antibodies
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441755

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002799146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002799146

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载